Home · Stock · ARCT

ARCT Arcturus Therapeutics Holdin

Which ETFs hold ARCT? Arcturus Therapeutics Holdin is held by 1 fund tracked by ETFpeek.

Held by 1 fund todayData as of 9 Oct 2026
HealthcareBiotechnology
$12.87
-32.1% 1y
$5.5052-week range$24.17
Market cap
$370M
3-month
+84.6%
CEO
Mr. Joseph E. Payne M.Sc.
Revenue · last 4 qtrs (-89.5% YoY)

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Provider

Currently Held By

ARK
ARKG
ARK Genomic Revolution ETF
Weight in fund1.77%
Shares held2,819,231
Market value$36.3M
View fund →
Not held by the selected provider.
last 90 days
No insider activity recorded in the last 90 days.
0 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
No trades recorded yet.
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds